SunWay Biotech Co., Ltd.(TW:1271)
NT$58.00+2.00 (+3.76%)
TW:1271
SunWay Biotech Co., Ltd. financials statements
NT$58.00
At close:+2.00 (+3.76%)
SunWay Biotech Co., Ltd. (1271) Ratios
SunWay Biotech Co., Ltd. Ratios
TW:1271's free cash flow for Q2 2026 was NT$25.42M. For the 2026 fiscal year, TW:1271's free cash flow was decreased by NT$-97.99M and operating cash flow was NT$123.41M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.62 | 3.69 | 3.99 | 2.35 | 8.72 |
| Quick Ratio | 1.23 | 2.75 | 3.16 | 1.85 | 7.45 |
| Cash Ratio | 0.62 | 1.31 | 1.78 | 0.66 | 5.71 |
| Solvency Ratio | 0.14 | 0.38 | 0.16 | 0.20 | 3.11 |
| Operating Cash Flow Ratio | 0.46 | 0.70 | 0.28 | 0.23 | 2.65 |
| Short-Term Operating Cash Flow Coverage | 0.89 | 26.77 | 2.36 | 0.65 | 8.84 |
| Net Current Asset Value | NT$ -410.32M | NT$ 298.35M | NT$ 356.57M | NT$ 250.42M | NT$ 467.99M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.20 | 0.07 | 0.08 | 0.15 | 0.03 |
| Debt-to-Equity Ratio | 0.27 | 0.08 | 0.09 | 0.25 | 0.04 |
| Debt-to-Capital Ratio | 0.21 | 0.07 | 0.09 | 0.20 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.37 | 1.16 | 1.14 | 1.66 | 1.12 |
| Debt Service Coverage Ratio | 0.70 | 18.21 | 2.85 | 0.60 | 10.40 |
| Interest Coverage Ratio | 9.25 | 25.43 | 25.14 | 34.02 | 1863.76 |
| Debt to Market Cap | 0.18 | 0.00 | 0.01 | 0.07 | 0.01 |
| Interest Debt Per Share | 14.86 | 4.23 | 9.99 | 3.60 | 0.62 |
| Net Debt to EBITDA | 2.97 | -0.19 | -0.70 | -1.08 | -1.71 |
| Profitability Margins | |||||
| Gross Profit Margin | 56.43% | 56.18% | 41.48% | 35.24% | 71.26% |
| EBIT Margin | 12.75% | 15.22% | 10.21% | 9.59% | 44.76% |
| EBITDA Margin | 19.88% | 23.84% | 14.57% | 11.41% | 50.07% |
| Operating Profit Margin | 10.48% | 14.53% | 9.18% | 9.22% | 44.09% |
| Pretax Profit Margin | 11.62% | 14.65% | 9.85% | 9.32% | 44.74% |
| Net Profit Margin | 10.22% | 12.22% | 8.07% | 7.06% | 44.36% |
| Continuous Operations Profit Margin | 10.22% | 12.22% | 8.13% | 7.37% | 44.61% |
| Net Income Per EBT | 87.93% | 83.45% | 81.97% | 75.81% | 99.15% |
| EBT Per EBIT | 110.84% | 100.79% | 107.24% | 101.02% | 101.47% |
| Return on Assets (ROA) | 2.27% | 3.13% | 1.26% | 6.28% | 27.77% |
| Return on Equity (ROE) | 3.11% | 3.63% | 1.44% | 10.43% | 31.04% |
| Return on Capital Employed (ROCE) | 2.62% | 3.95% | 1.52% | 13.47% | 30.66% |
| Return on Invested Capital (ROIC) | 2.16% | 3.27% | 1.23% | 8.63% | 29.46% |
| Return on Tangible Assets | 4.87% | 8.63% | 3.60% | 6.51% | 28.31% |
| Earnings Yield | 2.83% | 2.51% | 1.10% | 3.18% | 8.25% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.57 | 3.25 | 2.14 | 2.49 | 3.71 |
| Payables Turnover | 16.39 | 9.31 | 17.11 | 4.99 | 261.54 |
| Inventory Turnover | 2.28 | 2.02 | 1.98 | 2.93 | 1.42 |
| Fixed Asset Turnover | 1.70 | 1.91 | 1.32 | 78.32 | 7.82 |
| Asset Turnover | 0.22 | 0.26 | 0.16 | 0.89 | 0.63 |
| Working Capital Turnover Ratio | 2.20 | 1.60 | 1.33 | 1.18 | 0.89 |
| Cash Conversion Cycle | 240.39 | 253.33 | 333.71 | 197.88 | 353.66 |
| Days of Sales Outstanding | 102.29 | 112.22 | 170.30 | 146.45 | 98.29 |
| Days of Inventory Outstanding | 160.37 | 180.32 | 184.74 | 124.55 | 256.77 |
| Days of Payables Outstanding | 22.27 | 39.22 | 21.33 | 73.12 | 1.40 |
| Operating Cycle | 262.66 | 292.55 | 355.04 | 271.00 | 355.06 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 3.69 | 2.60 | 1.83 | 2.11 | 4.76 |
| Free Cash Flow Per Share | 1.97 | 0.55 | 0.32 | 1.99 | 4.47 |
| Dividend Paid and CapEx Coverage Ratio | 1.21 | 0.86 | 0.63 | 4.72 | 1.57 |
| Capital Expenditure Coverage Ratio | 2.14 | 1.27 | 1.21 | 16.44 | 16.41 |
| Operating Cash Flow Coverage Ratio | 0.25 | 0.63 | 0.18 | 0.60 | 7.77 |
| Operating Cash Flow to Sales Ratio | 0.22 | 0.16 | 0.10 | 0.10 | 0.42 |
| Free Cash Flow Yield | 3.31% | 0.70% | 0.23% | 4.24% | 7.38% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 35.36 | 39.95 | 90.85 | 31.45 | 12.07 |
| Price-to-Sales (P/S) Ratio | 3.61 | 4.87 | 7.35 | 2.22 | 5.37 |
| Price-to-Book (P/B) Ratio | 1.10 | 1.45 | 1.31 | 3.28 | 3.76 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 30.19 | 142.25 | 430.49 | 23.60 | 13.54 |
| Price-to-Operating Cash Flow Ratio | 16.10 | 30.13 | 74.94 | 22.17 | 12.72 |
| Price-to-Earnings Growth (PEG) Ratio | -2.47 | 1.34 | 67.69 | -0.45 | 0.49 |
| Enterprise Value Multiple | 21.14 | 20.26 | 49.71 | 18.37 | 9.02 |
| Enterprise Value | 4.17B | 4.68B | 4.14B | 891.81M | 1.72B |
| EV to EBITDA | 21.14 | 20.26 | 49.71 | 18.37 | 9.02 |
| EV to Sales | 4.20 | 4.83 | 7.24 | 2.10 | 4.52 |
| EV to Free Cash Flow | 35.11 | 140.93 | 424.47 | 22.30 | 11.39 |
| EV to Operating Cash Flow | 18.73 | 29.85 | 73.89 | 20.94 | 10.69 |
| Tangible Book Value Per Share | 14.68 | 14.02 | 27.00 | 13.46 | 15.86 |
| Shareholders’ Equity Per Share | 53.99 | 54.03 | 104.55 | 14.30 | 16.11 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.12 | 0.17 | 0.17 | 0.21 | 0.00 |
| Revenue Per Share | 16.44 | 16.07 | 18.67 | 21.11 | 11.27 |
| Net Income Per Share | 1.68 | 1.96 | 1.51 | 1.49 | 5.00 |
| Tax Burden | 0.88 | 0.83 | 0.82 | 0.76 | 0.99 |
| Interest Burden | 0.91 | 0.96 | 0.96 | 0.97 | 1.00 |
| Research & Development to Revenue | 0.04 | 0.06 | 0.01 | 0.10 | 0.11 |
| SG&A to Revenue | 0.42 | 0.36 | 0.31 | 0.26 | 0.16 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.93 | 1.10 | 1.26 | 1.07 | 0.94 |
Currency in TWD
